Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30024725 | 0.78 | KCNH2 (0.30) | KCNH2 | |
| SCHEMBL16878677 | 0.71 | — | — | |
| SCHEMBL16878090 | 0.70 | KCNH2 (0.39) | KCNH2 | |
| Piperazine SCHEMBL27775754 | 0.68 | HIF1A (0.86) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL27262335 | 0.68 | — | — | |
| SCHEMBL16877381 | 0.68 | — | — | |
| SCHEMBL16877333 | 0.67 | CCR5 (0.47) | HIF1AMAPTPDE4AKDRKCNH2 | |
| SCHEMBL16612279 | 0.67 | — | — | |
| SCHEMBL6264045 | 0.67 | — | — | |
| SCHEMBL28815512 | 0.67 | MAN1B1 (0.71) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025199636-A1 | TARGETED RADIOLIGAND COMPOUNDS AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2025-10-02 | — | — | WO | claimed |
| EP-4556029-A2 | RADIOPHARMACEUTICAL CONJUGATE | The South African Nuclear Energy Corporation Limited (ZA) | 2025-05-21 | — | — | EP | claimed |
| US-20250099632-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES UK LIMITED (GB) | 2025-03-27 | — | — | US | claimed |
| US-20250026739-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2025-01-23 | — | — | US | claimed |
| EP-4479040-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2024-12-25 | — | — | EP | claimed |
| US-20240382630-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES UK LIMITED (GB) | 2024-11-21 | — | — | US | claimed |
| US-12145926-B2 | Compounds and radioligands for targeting neurotensin receptor and uses thereof | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-11-19 | — | — | US | claimed |
| EP-4436979-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2024-10-02 | — | — | EP | claimed |
| US-20240287046-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-08-29 | — | — | US | claimed |
| CN-118451091-A | Cleavable radioligands for targeting cell surface receptors and uses thereof | 辐联科技香港有限公司 | 2024-08-06 | — | — | CN | claimed |
| EP-3917499-A1 | ADHESIVE/ADSORPTION SWITCH ON NANOPARTICLES TO INCREASE TUMOR UPTAKE AND DELAY TUMOR CLEARANCE | The Johns Hopkins University (US) | 2021-12-08 | — | — | EP | claimed |
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2020-12-29 | — | — | US | claimed |
| WO-2020160147-A1 | ADHESIVE/ADSORPTION SWITCH ON NANOPARTICLES TO INCREASE TUMOR UPTAKE AND DELAY TUMOR CLEARANCE | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-06 | — | — | WO | claimed |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | UNIVERSITY OF CAPE TOWN (ZA) | 2017-10-19 | — | — | US | claimed |
| EP-3197504-A2 | RADIOPHARMACEUTICAL CONJUGATE OF A METABOLITE AND AN EPR AGENT, FOR TARGETING TUMOUR CELLS | The South African Nuclear Energy Corporation Limited (ZA) | 2017-08-02 | — | — | EP | claimed |
| WO-2016046793-A2 | RADIOPHARMACEUTICAL CONJUGATE | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2016-03-31 | — | — | WO | claimed |
| JP-4850391-B2 | — | — | 2012-01-11 | — | — | JP | claimed |
| US-20050191243-A1 | Responsive paramagnetic mri contrast agents | BRACCO IMAGING S.P.A. (IT) | 2005-09-01 | — | — | US | claimed |
| EP-1469890-A1 | RESPONSIVE PARAMAGNETIC MRI CONTRAST AGENTS | Bracco Imaging S.p.A. (IT) | 2004-10-27 | — | — | EP | claimed |
| WO-2003063912-A1 | RESPONSIVE PARAMAGNETIC MRI CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2003-08-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026739-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | NTSR1, NTSR2, NPSR1 | HIF1A 3072/4885MAPT 1937/4885PDE4A 3068/4885 |
| US-20240382630-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | ASGR1, GNRHR, SCTR | HIF1A 2876/4885MAPT 4477/4885PDE4A 4146/4885 |
| US-20240287046-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | NTSR1, NTSR2, NPSR1 | HIF1A 2977/4885MAPT 1727/4885PDE4A 3048/4885 |
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | EPRS1, FOLH1, SLC46A1 | HIF1A 318/4885MAPT 3477/4885PDE4A 4626/4885 |
| US-20250099632-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | ASGR1, GNRHR, SCTR | HIF1A 2876/4885MAPT 4477/4885PDE4A 4146/4885 |
| US-12145926-B2 | Compounds and radioligands for targeting neurotensin receptor and uses thereof | NTSR1, NTSR2, NPSR1 | HIF1A 2977/4885MAPT 1727/4885PDE4A 3048/4885 |
| US-20050191243-A1 | Responsive paramagnetic mri contrast agents | MYT1, PRTN3, CECR2 | HIF1A 146/4885MAPT 915/4885PDE4A 415/4885 |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | FOLH1, EPRS1, FOLR1 | HIF1A 528/4885MAPT 3460/4885PDE4A 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.